Further information Decision makers have concluded that the clear rationale to not evaluate this product is due to it being a change to the formulation of an existing product as per section 7.1.3 of ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A list of downloadable documents created during development.

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A list of downloadable documents created during development.

Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

You can now review and comment on the proposed changes to the appeal period for technology appraisal and highly specialised technologies appeals.

When NICE recommends a treatment as an option for use with managed access, NHS England will make it available according to the conditions in the managed access agreement. See section 4f of The ...